sions with ostial LCX stenting. The follow-up angiography was performed at 8 months after procedure. Exclusion criteria included the following: bare metal stenting, hybrid stenting, in-stent restenosis at the ostial site of the LCX, trifurcation lesions, and previous LMT to left anterior descending coronary artery crossover stenting. The primary endpoints of our study were main and side branch restenoses and target lesion revascularization (TLR) at 8-month followup. Results: In LMT-LCX crossover stenting and ostial LCX stenting, the restenosis rates were 20.5% (8/39) and 40.1% (9/22) (p=0.008), the TLR rates were 12.8% (5/39) and 36.4% (8/22) (p=0.0031), and the clinically driven TLR rates were 7.7% (3/39) and 13.7% (3/22) (p=03458). Conclusion: The TLR rate was higher in ostial LCX stenting than in LMT-LCX crossover stenting. LMT-LCX crossover stenting may be more favorable if possible. (EES 455; SES 257) and the population without STEMI consisted of 890 patients (EES 447; SES 443). Of these patients, 32.8% presented with stable angina and 22.7% with unstable angina or non-STEMI. In the STEMI population, EES patients had more calcified lesions and on average shorter stent length compared to SES patients. Other characteristics were balanced. At two-years, EES use was associated with a trend toward a reduction in the primary endpoint compared to SES (6.0% vs. 9.3%, HR 0.63, 95% CI 0.36-1.09, p=0.097), a significant reduction in the alternative composite endpoint (6.9% vs. 11.7%, HR 0.58, 95% CI 0.35-0.95, p=0.031) and a trend toward reduced early definite/ probable ST (0.7% vs. 2.3%, p=0.057). In the population without STEMI, EES patients less frequently had prior hypertension, coronary interventions and calcified lesions compared to SES. In these patients, no differences in clinical outcomes at 2-years were observed between the stents. Conclusion: In STEMI patients, randomization to EES was associated with trends toward reducing the primary endpoint and early ST rate compared to SES during 2-year follow-up. Furthermore, the post hoc defined alternative composite endpoint was significantly reduced in EES patients. No differences in clinical endpoints between EES and SES were observed in patients presenting with a diagnosis other than STEMI, hinting at an advantage of EES over SES in the prothrombotic environment of STEMI. Aims: To scrutinize "limitations" of Drug-Eluting Stent (DES) use in contemporary "all-comer DES" practice responsible for continued Bare-Metal Stent (BMS) usage of 20-30%, i.e. contraindications to DES/double-antiplatelet therapy and limited DES benefits assumed in certain patient subgroups. Methods and results: A prospective registry of patients undergoing coronary stenting was conducted in 9 European centers over 11.7 months, together with the BASKET-PROspective Validation Examination (BASKET-PROVE), analyzing reasons for DES exclusions. In addition, subgroup analyses of all 2314 BASKET-PROVE patients were performed for 2-year rates of death/Myocardial Infarction (MI) and Target-Vessel Revascularization (TVR). Of 5353 consecutive patients, 4200 (78.5%) with target vessels 3.0-4.0mm were "possible DES candidates": half of them (n=2099) were excluded from BASKET-PROVE: for relative contraindications to DES/antiplatelet therapy (16.8%), for other study-related reasons (32%) or for unknown reasons (1.2%). Relative contraindications were increased bleeding risk (30%), planned surgery (26%) and no compliance expected (44%). A DES versus BMS benefit was found for death/MI in all BASKET-PROVE subgroups except for patients with stable angina and stent sizes >3.0mm (12% of all patients; interaction favoring BMS, p=0.03). All subgroups benefitted from up to 50% reduced TVR with DES.
Purpose: Randomized data comparing everolimus-eluting stents (EES) and sirolimus-eluting stents (SES) in patients with ST-segment elevation myocardial infarction (STEMI) are limited. The current analysis sought to compare 2-year clinical outcomes of EES and SES in patients with and without STEMI. Methods: A patient-level pooled analysis of the XAMI (a prospective trial randomizing 625 acute MI patients to EES or SES) and APPENDIX-AMI (an open-label trial randomizing 977 all-comer patients to EES or SES) trials was performed. Patients were stratified according to randomized stent and presenting diagnosis. The primary endpoint consisted of cardiac mortality, MI and target vessel revascularization (TVR) during 2-year follow-up. Secondary endpoints were the post hoc defined alternative composite endpoint (all-cause mortality, MI, TVR), individual components of the composite and definite/probable stent thrombosis (ST). Comparison was done using χ 2 test and log rank test for Kaplan Meier curves. Results: STEMI was the presenting diagnosis in 712 patients (EES 455; SES 257 ) and the population without STEMI consisted of 890 patients (EES 447; SES 443) . Of these patients, 32.8% presented with stable angina and 22.7% with unstable angina or non-STEMI. In the STEMI population, EES patients had more calcified lesions and on average shorter stent length compared to SES patients. Other characteristics were balanced. At two-years, EES use was associated with a trend toward a reduction in the primary endpoint compared to SES (6.0% vs. 9.3%, HR 0.63, 95% CI 0.36-1.09, p=0.097), a significant reduction in the alternative composite endpoint (6.9% vs. 11.7%, HR 0.58, 95% CI 0.35-0.95, p=0.031) and a trend toward reduced early definite/ probable ST (0.7% vs. 2.3%, p=0.057). In the population without STEMI, EES patients less frequently had prior hypertension, coronary interventions and calcified lesions compared to SES. In these patients, no differences in clinical outcomes at 2-years were observed between the stents. Conclusion: In STEMI patients, randomization to EES was associated with trends toward reducing the primary endpoint and early ST rate compared to SES during 2-year follow-up. Furthermore, the post hoc defined alternative composite endpoint was significantly reduced in EES patients. No differences in clinical endpoints between EES and SES were observed in patients presenting with a diagnosis other than STEMI, hinting at an advantage of EES over SES in the prothrombotic environment of STEMI. Aims: To scrutinize "limitations" of Drug-Eluting Stent (DES) use in contemporary "all-comer DES" practice responsible for continued Bare-Metal Stent (BMS) usage of 20-30%, i.e. contraindications to DES/double-antiplatelet therapy and limited DES benefits assumed in certain patient subgroups. Methods and results: A prospective registry of patients undergoing coronary stenting was conducted in 9 European centers over 11.7 months, together with the BASKET-PROspective Validation Examination (BASKET-PROVE), analyzing reasons for DES exclusions. In addition, subgroup analyses of all 2314 BASKET-PROVE patients were performed for 2-year rates of death/Myocardial Infarction (MI) and Target-Vessel Revascularization (TVR). Of 5353 consecutive patients, 4200 (78.5%) with target vessels 3.0-4.0mm were "possible DES candidates": half of them (n=2099) were excluded from BASKET-PROVE: for relative contraindications to DES/antiplatelet therapy (16.8%), for other study-related reasons (32%) or for unknown reasons (1.2%). Relative contraindications were increased bleeding risk (30%), planned surgery (26%) and no compliance expected (44%). A DES versus BMS benefit was found for death/MI in all BASKET-PROVE subgroups except for patients with stable angina and stent sizes >3.0mm (12% of all patients; interaction favoring BMS, p=0.03). All subgroups benefitted from up to 50% reduced TVR with DES.
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Conclusions:
In contemporary "all-comer DES" settings, every 6th patient presents with relative contraindications to DES/dual antiplatelet therapy precluding DES use. A DES versus BMS benefit in 2-year outcomes was found in all patient subgroups except for patients with stable angina and vessels >3.0mm: they seem to benefit less from DES regarding death/MI, however, if treated with BMS, the "cost" remains higher TVR rates. Purpose: The second generation everolimus eluting vascular scaffold (BVS) has been evaluated in the ABSORB clinical trial program. Patients with acute coronary syndromes (ACS) were excluded from those trials and at the current state of the art, no data are available on the performance of the BVS in patients presenting with ACS with or without ST-segment elevation (STEMI and NSTEMI). We report for the first time data after implantation of the BVS specifically in patients with ACS. Methods: Unselected consecutive patients presenting with acute coronary syndromes with or without ST-segment elevation (STEMI or NSTEMI) were implanted with second generation BVS. Procedural data and short-term clinical outcomes were prospectively evaluated. Results: A total of 49 patients presenting with ACS (35 NSTEMI and 13 STEMI) were implanted with second generation BVS. Mean age was 59±10 years, male gender in 78% of cases; the majority of lesion were located in left anterior descending coronary artery (LAD 53%, CX 23%, RCA 24%); moderate or severe calcification were observed in 46% of lesions. BVS was successfully implanted in 96% of cases (in 2 cases, 1NSTEMI and 1STEMI, the BVS failed in crossing the lesion). BVS overlap was performed in 12 patents and in 2 cases bifurcation lesions were successfully treated with provisional approach. The mean follow-up period was 73±41 days and no cases of target lesion revascularization, myocardial infarction, cardiac death and scaffold thrombosis were reported. Conclusions: The present report is the first investigating the performance of second generation BVS in patients with acute coronary syndromes. Our data suggest feasibility of implantation of this novel device in patients with NSTEMI or STEMI with a high procedural success rate and excellent short-term clinical outcomes.
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The association between incomplete stent apposition, multiple interstrut hollows, and in-stent thrombus formation in lesions after drug-eluting stent implantation T. Tada, K. Kadota, S. Habara, H. Tanaka, Y. Fuku, T. Goto, K. Mitsudo. Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan Purpose: Incomplete stent apposition (ISA) assessed with intravascular ultrasound was known as one of risk factors for stent thrombosis. Meanwhile it was reported that peri-stent contrast staining (PSS) was associated with very late stent thrombosis, and was also reported that ISA and multiple interstrut hollows (MIH) were observed in the lesions with PSS using optical coherence tomography (OCT). However, little is known about the association between ISA, MIH, and in-stent thrombus formation in lesions after drug-eluting stent (DES) implantation. Methods: Between May 2008 and January 2013, we performed OCT for 328 in-stent restenosis lesions after DES implantation. Cross-sectional OCT images Figure 1 were analyzed at every 1 mm of the stented site and qualitative assessment of existence of ISA, MIH, and thrombus was performed. ISA was defined as separation of at least 1 stent strut from the vessel wall, and MIH is defined as multiple hollows (the maximum depth >0.5 mm) existing between and outside well-apposed stent struts. The difference in the incidence of in-stent thrombus formation was compared between lesions with and without ISA and MIH. Thrombus was defined as masses protruding into the vessel lumen with a dimension >250 μm. Red thrombus was high-backscattering protrusion with high attenuation. White thrombus was signal-rich low backscattering protrusion with low attenuation. Results: The patients were 271 men and 57 women and the mean age was 68.9±9.4 years. The mean follow-up period from stent implantation was 1.62±1.53 years. The results are shown in the figure. Conclusion: ISA assessed with OCT might to be one of risk factors for in-stent thrombus formation in restenosis lesions after DES implantation. MIH might have an effect on only the formation of red thrombus. Predilation of coronary lesions has been recommended before bioabsorbable vascular scaffolding (BVS). However, there is no information on the routinary use of direct BVS implantation in patients with coronary artery disease (CAD). The purpose of this study was to analyze the feasibility and safety of direct BVS implantation without plaque pre-conditioning by balloon dilation. From 117 patients with CAD (mean age 57±10 years) treated by BVS in 159 lesions, we analyzed the procedure in those in which direct implantation was first attempted (118,14%). Elective predilation was carried out if the ultrasound study showed a heavy calcified plaque, if the IVUS probe could not cross the lesion or if the lesion was occlusive, being these lesions excluded of the study. All lesions were analyzed by angiography and ultrasonography (IVUS) before and after the treatment. In 35 lesions (29%) the final result was also evaluated by optical coherence tomography (OCT). Direct implantation was successfully achieved in 102 lesions (86%). In the remaining 16 stenosis (14%) it was not possible to cross; then, the device was retrieved and sucessffully implanted after lesion predilation. Failure to cross never originated the need for a new device. Need for post-dilation (residual stenosis, underexpansion or no-apposition) was observed in 40 lesions (34%). A larger plaque burden was a factor associated with failure to directly cross the lesion (84% vs 77%, p =0.037). Proximal or distal edge dissection, as evaluated by angiography was not observed. However by IVUS and/or OCT, minor edge dissection were detected in 10 lesions (8%),proximal edge in 4 and distal edge in 6. Additional stent was not needed at the borders. Conclusions: Direct BVS implantation is safe and feasible in most soft and echolucent coronary plaques. A larger plaque burden at the minimal lumen area is associated with failure for direct implantation. When this occur, the device can be safely retrieved and reimplanted after predilation.
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S. Homs, G. Roura, J. Gomez-Lara, J.L. Ferreiro, R. Romaguera, G. SanchezElvira, L. Teruel, J.A. Gomez-Hospital, A. Cequier. Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Spain Background and aim: Several studies have reported some grade of endothelial dysfunction (ED) after sirolimus-eluting stent, paclitaxel-eluting stent and zotarolimus eluting stent implantation, but up to date, the effects of everolimuseluting stent (EES) on endothelial vasomotor function are not well known. The aim of this study was to evaluate the grade of ED in patients with EES compared to patients with bare metal stent (BMS) implantation. Methods: Consecutive patients with successfully EES implantation were included in the experience. The control group consisted in 15 patients successfully treated with BMS. A coronary arteriography and an intracoronary acetylcholine (Ach) ED test were performed to all patients 6 months after stent implantation. Quantitative coronary angiography analysis was performed by two experienced operators evaluating changes in mean luminal diameter (MLD) of the segment distal to the stent after increasing doses of Ach. To minimize the potential influence of differences in baseline characteristics among groups, a general linear model was used to analyze the changes in MLD in response to intracoronary Ach infusion, unadjusted and adjusted by stent length, in-stent late loss and baseline MLD as covariates. Results: Fifteen patients with EES and 15 patients with BMS were included. EES group presented a MLD variation of 3.14% after Ach highest dose infusion. BMS group showed a variation of 2.35% with no statistically significant difference (3.14% vs 2.35% p >0.05) When the comparison was performed with adjusted data, (Figure 1 ) despite a numerical tendency of higher degree of vasoconstriction in EES group compared to BMS no statistically significant difference was found. Conclusions: EES implantation is not related with a higher ED grade compared to BMS implantation. ) and Everolimus (Xience V ® ) coated stents were performed in elective PCI patients. Within the STRESSED (direct Stenting To Reduce REStenosis in Stent Era with Drug elution) trial a sub analysis was performed comparing the incidence of restenosis and clinical outcome in both stents. Methods: Within the STRESSED trial a total of 600 patients with stable or unstable angina pectoris or a recent (<30 days) myocardial infarction were randomized to different revascularisation strategies. The first 50% of patients were treated with an Endeavor stent and the second 50% with a Xience V stent. The primary end-
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